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ABSTRACT 
Objective: To develop simple, precise, rapid, and accurate RP-HPLC method for the simultaneous estimation of Febuxostat and Naproxen in 
synthetic mixture. To perform complete validation of newly developed analytical methods as per ICH(Q2) R1 [32]
Methods: In RP-HPLC method for Febuxostat and Naproxen, chromatographic separation was carried out on Shimandzu LC-20AT, Hypersil BDS 
column (250mm x 4.6mm, 5 μm) using mobile phase ACN: Methanol: Phosphate Buffer (50:35:15 v/v) pH 5, detected at 288 nm, with flow rate 
1.0ml/min and injection volume 20 μL.  
 Guideline. 
Results: For RP- HPLC Linearity of Febuxostat and Naproxen were found to be 4 – 12 μg/ml and 25 - 75 μg/ml respectively. For both the developed 
and validated methods the %RSD was found to be less than 2% and the % recovery was found to between 98-102 %.  
Conclusion: The developed and validated method was found to be simple, accurate, economical, robust and reproducible. There was no 
interference of any diluent and excipient in the determination of drugs from synthetic mixture. So, the method can be successfully applied for 
routine Quality control analysis. 




5-carboxylic acid) (ULORIC) (Figure 1) is a xanathine oxidase (XO) 
inhibitor indicated in patients with gout suffering from 
hyperuricemia and is used in its chronic management. Febuxostat 
received marketing approval by the European Medicines Agency on 
April 21, 2008 and was approved by the U.S. Food and Drug 
Administration on February 16, 2009. [1] It is freely soluble in 
Dimethylformamide; soluble in Ethanol; soluble in Methanol and 
Acetonitrile and practically insoluble in Water. [2] Naproxen(+)-(S)-2-(6-
methoxynaphthalen-2-yl) propanoic acid (figure 2) is an anti-
inflammatory agent with analgesic and antipyretic properties. Naproxen 
is commonly used for the reduction of pain, fever, inflammation and 
stiffness caused by conditions including migraine, osteoarthritis, kidney 
stones, rheumatoidarthritis,gout, ankylosingspondylitis, tendinitis.[1] 
Soluble in Water, Methanol and Ethanol, slightly soluble in Acetone, 




Fig. 1: Febuxostat [3] 
 
 
Fig. 2: Naproxen [3] 
Febuxostat is used as anti-gout.Naproxen is used as gout 
suppressant and pain killer. Combination of Febuxostat and 
Naproxen increases the Cmax and AUC Absorption of Febuxostat 
increases by 40%. Literature review revealed that there are several 
methods like U.V. Spectrophotometry [4-8], HPLC[9-31]
MATERIALS AND METHODS 
 avalilabe for 
estimation of Febuxostat and Naproxen as single formulation and in 
combination with other drugs. But literature review revealed that 
there is no method available for Simultaneous estimation of 
Febuxostat and Naproxen in combination. Thus, this article presents 
the simultaneous estimation of Febuxostat and Naproxen in 
synthetic mixture. 
Methanol HPLC grade and Acetonitrile HPLC grade was procured 
from E. Merck Ltd, Mumbai. Orthophosphoric acid, Potassium 
Dihydrogen phosphate was procured from Astron chemicals, 
Ahmedabad. The analysis of drug was carried out on a SHIMADZU 
LC2010 series HPLC system equipped with a reverse phase Hypersil 
C18 column (250×4.6mm, 5µm n particle size) a LC 20 AT isocratic 
pump, a 20µl injection loop and a SPD- 20 A Promenence UV- Visible 
Detector and running on Spinchrom Chromatographic Software 
version. Isocratic elution with 0.5 mM Phosphate buffer: Methanol: 
acetonitrile (ACN) (15: 35: 50 v/v) is used at a flow rate of 1 ml/ 




The contents of mobile phase were Methanol, ACN, and phosphate 
buffer adjusted to pH 5 with 5% Orthophosphoric acid. These were 
filtered through 0.45µ membrane filter and degassed by sonication 
for use. The flow rate for mobile phase was optimized to 1ml/min. 
The run time was set at 20 min and column temperature was 
maintain at ambient (room temperature). The volume of injection 
was 20 µL, and eluent was detected at 288 nm.  
Method 
The RP-HPLC method of Febuxostat and Naproxen were achieved by 
isocratic elution technique with UV-VIS Detector. Febuxostat and 
Naproxen were determined at 288nm respectively with the 
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concentration range of 4-12 µg/ml for Febuxostat and 25-70 µg/ml 
for Naproxen respectively. For analysis of synthetic mixture, the 
powder of 10 mg of Febuxostat and 62.5 mg of Naproxen was taken, 
dissolved in 100 ml volumetric flask and made up to 100 ml with 
Methanol. The solution was sonicated for 15min and filtered 
through Whatmann filter paper No.41. From clear solution, further 
dilutions were made to get 10 µg/ml of Febuxostat and Naproxen. 
Standard Stocks Solutions of binary mixture 
About 10 mg of Febuxostat and 62.5 mg Naproxen weighed 
accurately and transferred to 100 ml volumetric flask and dissolved 
in methanol. This solution was sonicated for about 15 min and make 
up to the mark with methanol to get the concentration of 100 µg/ml 
Febuxostat and 625 µg/ml Naproxen. 
Method validation 
Specificity 
A blank solution (mobile phase) and Common excipients like starch, 
lactose, magnesium stearate were dispersed in methanol, filtered 
and injected. The chromatogram showed no inferring peaks at 




Fig. 3: Chromatogram of mobile phase 
 
 
Fig. 4: Chromatogram of excipients 
 
 
Fig. 5: Chromatogram of binary mixture (nap-3.53 min and feb-4.83 min) 
 
Table 1: Linearity data 
Febuxostat Naproxen 
Conc.(µg/ml) Mean Area± SD %RSD Conc.(µg/ml) Mean Area± SD % RSD 
4 368594.3 ± 525.696 0.14 25 511140.3 ± 1090.314 0.21 
6 421046.3±1161.009 0.27 32.5 572052.3 ± 3107.962 0.54 
8 473462.3 ± 1077.19 0.22 50 638483.7 ± 5802.145 0.90 
10 527129.3 ±1776.04 0.33 62.5 705566.3 ± 5342.425 0.75 




Linearity and range  
Aliquots of standard stock solutions of Febuxostat and Naproxen 
were taken in 10 ml volumetric flasks and diluted with mobile phase 
to get final concentrations in range of 4-12μg/ml for Febuxostat and 
25-75μg/ml for Naproxen. Triplicate injections were made for each 
concentration.  
 
Fig. 7: Febuxostat (4-12 μg/ml) 
 
The plots of peak area versus respective concentrations of 
Febuxostat and Naproxen were found to be linear in the 
concentration range of 4-12μg/ml and 25-75μg/ml respectively. The 
linear regression equations of the lines are:  
For Febuxostat -y = 26375x + 262916, (r2 = 1)  
For Naproxen -y = 5250.8x + 377336, (r2 = 0.9998)  
For Febuxostat 
Precision  
Precision study was performed as per ICH Q2 (R1)[32]
Drug Name 
 to find out 
repeatability, intra-day and inter-day variations. For the precision, 
three replicates of each concentration are injected into the system 
and results are reported in terms of relative standard deviation as 
given in table No. 2,3and 4 respectively. 
Table 2: Repeatability data 
Febuxostat Naproxen 
Wavelength 288 nm 
Concentration 8 µg/ml 50 µg/ml 
MEAN±SD(n=3) 550955.8 ± 940.8129 723179.3 ± 1961.269 
%RSD 0.17 0.27 
 
 
Fig. 8: Naproxen (25-75 μg/ml) 
 
Accuracy 
The accuracy was determined by recovery studies. The recovery 
studies were performed by standard addition method, at 80%, 
100%, 120% level. Percent recovered was calculated using 
regression equation. 
Limit of Detection and Limit of Quantitation  
The limit of detection (LOD) is the smallest concentration that can 
be detected but not necessarily quantified as an exact value. 
LOD = 3.3 × Standard deviation of y intercept /Slope of calibration 
curve  
Febuxostat – 0.105μg/ml 
Naproxen – 1.93μg/ml 
The LOQ is the lowest amount of analyte in the sample that can be 
quantitatively determined with suitable precision and accuracy.  
LOQ = 10 × Standard deviation of y intercept/ Slope of calibration 
curve  
Febuxostat – 0.316μg/ml  
Naproxen – 5.86μg/ml 
Applicability to synthetic mixture 
Applicability of proposed method was tested by analyzing the 
synthetic mixture. 
 
Table 3: Intraday precision data 
Febuxostat 
Wavelength = 288 nm 
Naproxen 
Wavelength = 288 nm 
Conc. 
(µg/ml) 
Mean Area ± SD % RSD Conc.  
(µg/ml) 
Mean Area ± SD % RSD 
6 441926.3 ± 619.1545 0.14 37.5 591421.3 ± 282.2788 0.04 
10 552418.3 ± 711.5703 0.12 62.5 725942 ± 233.8269 0.03 
14 661356.7 ± 807.8814 0.12 87.5 858148.3 ± 2791.556 0.3 
 
Table 4: Interday precision data 
Febuxostat 
Wavelength = 288 nm 
Naproxen 
Wavelength = 288 nm 
Conc. 
(µg/ml) 
Mean Area ± SD % RSD Conc.  
(µg/ml) 
Mean Area ± SD % RSD 
6 435200.3 ± 11232.98 1.39 37.5 584190.7 ± 2263.98 1.46 
10 543938 ± 14944.42 0.72 62.5 717163.7 ± 5088.96 0.69 




Table 5: Accuracy data 
Drug name % Level of Recovery Total amount (µg/ml) Total amount obtained 
(n=3) ± SD 
Area 
± SD 
% Recovery ± SD 
Feb 80 % 7.2 7.1±0.03 409975±139.0 99.5 %±0.0577 
100 % 8.0 8.0±0.04 457843±724.6 100.8 %±0.12 
120 % 8.8 8.7±0.01 494441±1460 99.59 % ±0.31 
Nap 80 % 45 44.7±0.43 464680±3766 99.41 % ±0.91 
100 % 50 50.9±0.51 516868±4662 100 %±1.02 
120 % 55 55.26±0.80 555129.3±731 99.52%±1.46 
 
 
Fig. 6: Chromatogram of synthetic mixture 
 
Table 7: Applicability to synthetic mixture Data 
Synthetic mixture Drug Amount taken in synthetic mixture Amount found (mg) (n=3) ± SD.  
 
%Amount obtained ± SD. 
Febuxostat 40 mg 39.8 ± 0.52 99.5% ± 0.125 
Naproxen 250 mg 251.0 ± 0.763 100.4% ± 1.014 
 
RESULT 
Table 8: Optical regression characteristics and validation parameters 
S. No. Parameters Febuxostat Naproxen 
1 Wavelength (nm) 288 nm 
2 Beer’s Law Limit (μg/ml) 4 – 12 25 – 75 
3 Regression equation 
(y = mx +c) 
y = 26375x + 262916 y = 5250.8x + 377336 
4 Slope (m) 26375 5250.8 
5 Intercept (c) 262916 377336 
6 Correlation Coefficient (r²) 1.0 0.999 
7 Repeatability (% RSD, n=6) 0.17 0.27 
8 Interday (n=3) (% RSD) (μg/ml) 1.5 – 1.7 1.0 – 2.0 
9 Intraday(n=3) (% RSD) (μg/ml) 0.12 – 0.14 0.03 – 0.3 
10 LOD(μg/ml) 0.105 1.93 
11 LOQ(μg/ml) 0.319 5.86 
12 Accuracy 99.5-100.8 % 99.4-100 % 
 
CONCLUSION 
A Simple, specific, accurate, and precise RP-HPLC method has been 
developed and validated for simultaneous estimation of both these 
drugs. The chromatographic separation was achieved on Hypersil 
BDS coloumn (250 mm x 4.6mm, 5μm) in size column using ACN: 
Methanol: Phosphate Buffer (50:35:15 v/v) as mobile phase at 288 
nm. 
The plot of area versus respective concentration of Febuxostat and 
Naproxen was found to be linear in the concentration range of 4-12 
μg/ml for Febuxostat and 25- 75 μg/ml for Naproxen with r2 = 1 for 
Feb and r2 
Precision was calculated as repeatability, interday and intraday 
variations and % RSD was found to be less than 2% for both the 
drugs. 
= 0.998 for Nap respectively. 
Mean % recovery for Febuxostat and Naproxen were found to be 
100.8 % and 99.52 % respectively. Recovery is in the range of 98-
102 %, indicates that method is accurate.  
System suitability test reveals that all system suitability parameters 
complies standard values. 
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